Cenderitide
Also known as: CD-NP, CD‑NP, Cenderitide
Source Cenderitide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Cenderitide (CD‑NP) is a designer natriuretic peptide engineered by fusing C‑type natriuretic peptide to the C‑terminus of dendroaspis natriuretic peptide. It is being investigated as an intravenous or subcutaneous therapy for heart failure and related cardiorenal disorders, aiming to enhance renal function and limit cardiac fibrosis while avoiding marked blood‑pressure drops.
Mechanism of Action
Cenderitide simultaneously activates the particulate guanylyl cyclase receptors GC‑A and GC‑B. This dual engagement raises intracellular cyclic GMP in vascular, renal and myocardial cells, promoting natriuresis, vasodilation, anti‑fibrotic signalling and inhibition of renin‑angiotensin activity. The design seeks to preserve the renal‑enhancing and anti‑fibrotic effects of GC‑B activation without the hypotensive response often seen with GC‑A‑selective agonists.
What the Research Shows
Pre‑clinical work described Cenderitide as a dual‑receptor activator with resistance to enzymatic degradation. Early‑phase human data (four‑hour IV infusion in stable chronic heart‑failure patients) showed it was safe, well‑tolerated, and produced significant rises in plasma and urinary cGMP without altering blood pressure. Review articles place it among novel vasodilators under development for acute heart failure, and a recent genome‑wide association study highlighted NPR2 (the receptor target) as a sex‑specific heart‑failure drug target, noting Cenderitide’s phase‑2 trial status. Overall, evidence consists of mechanistic rationale, small safety studies, and ongoing clinical evaluation.
Reported Benefits
Available data indicate Cenderitide can increase circulating and urinary cGMP, reflecting target engagement, and does so without causing hypotension—a common limitation of other natriuretic peptides. Its dual receptor activation is intended to provide renal‑protective and anti‑fibrotic benefits, potentially improving volume control and cardiac remodeling in heart‑failure patients.
Limitations of the Evidence
Clinical evidence is limited to a single short‑duration safety study in a small stable‑HF cohort; efficacy outcomes such as symptom relief, renal function improvement, or long‑term remodeling have not been demonstrated. Larger, longer‑term trials are needed to confirm benefits, optimal dosing, and to assess effects in acute decompensated settings. Sex‑specific genetic insights are preliminary and do not yet translate to proven therapeutic advantage.
Safety Considerations
In the reported human infusion study, Cenderitide was well‑tolerated, with no serious adverse events and no change in blood pressure, suggesting a favorable acute safety profile. Nonetheless, the compound remains investigational, and comprehensive safety data—including chronic administration, rare adverse events, and interactions with standard heart‑failure therapies—are still pending.
How It Is Administered
Cenderitide is formulated for parenteral use, having been administered as a continuous intravenous infusion over four hours in early clinical trials. Subcutaneous delivery is also listed as a potential route, but detailed formulation and dosing regimens have not been fully disclosed in the published literature.
Routes of Administration
Goals & Uses
- Blood pressure reductionCardiovascularLow
- Chronic heart failure treatmentCardiovascularModerate
- Natriuresis and diuresis promotionRenal/CardiovascularModerate
- Renal protection in heart failureRenalLow
- Acute decompensated heart failure managementCardiovascularModerate
- Renal protectionRenalModerate
- Renin-angiotensin-aldosterone system suppressionNeurohormonalModerate
Contraindications
- Cardiogenic shockCardiovascularHigh
- Hypersensitivity to natriuretic peptidesImmunologicalHigh
- Acute decompensated heart failure with high filling pressuresCardiacModerate
- Severe renal failure (anuria)RenalModerate
- Severe hypotensionCardiovascularHigh
Adverse Effects
- Increased serum creatinineRenalUncommon
- Injection site reactionsLocalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularCommonLow blood pressure
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Antihypertensive agentsModerate
- ACE inhibitors / ARBsModerate
- Other vasodilators (e.g., nitrates, ACE inhibitors)Moderate
- DiureticsModerateMay worsen dehydration or electrolyte imbalance
Population Constraints
- Pediatric patientsAgeRelative
- Elderly patients (≥75 years)AgeRelative
- Pregnant womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalNot approved; clinical studies in progress
- United StatesInvestigationalPhase II trials ongoing
- United KingdomInvestigationalUnder MHRA review for trial authorization
Not approved in any major jurisdiction; currently in Phase II clinical development for chronic heart failure with reduced ejection fraction.
Evidence & Sources
- Journal ArticleUngradedWojta J2016-01-01T00:00:00.000000Z
- Journal ArticleModerateSingh A, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleLowYang Q, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateIchiki T, Dzhoyashvili N, Burnett JC Jr2019-01-01T00:00:00.000000Z
- Journal ArticleModerateKawakami R, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleLowMeems LMG, Burnett JC Jr2016-01-01T00:00:00.000000Z
Frequently Asked Questions
What distinguishes Cenderitide from other natriuretic peptides?
Cenderitide is engineered to activate both GC‑A and GC‑B receptors, aiming to combine renal‑enhancing and anti‑fibrotic effects while minimizing the hypotension commonly seen with GC‑A‑selective agents such as nesiritide.
Has Cenderitide been shown to improve heart‑failure outcomes?
To date, only a short‑term safety study in stable heart‑failure patients has been reported, demonstrating increased cGMP without blood‑pressure changes. No data yet confirm improvements in symptoms, hospitalization rates, or mortality.
Is Cenderitide approved for clinical use?
No. Cenderitide remains an investigational peptide in early clinical development and is not approved by regulatory agencies for any indication.
How is Cenderitide administered in studies?
In the published human trial, it was given as a continuous intravenous infusion for four hours. Subcutaneous administration is listed as a possible route, but specific protocols have not been disclosed.
What safety concerns should be considered?
Early data show a favorable acute safety profile with no hypotension or serious adverse events, but larger studies are required to assess long‑term safety, rare adverse effects, and interactions with standard heart‑failure medications.
What is Cenderitide?
Cenderitide (CD‑NP) is a designer natriuretic peptide engineered by fusing C‑type natriuretic peptide to the C‑terminus of dendroaspis natriuretic peptide. It is being investigated as an intravenous or subcutaneous therapy for heart failure and related cardiorenal disorders, aiming to enhance renal function and limit cardiac fibrosis while avoiding marked blood‑pressure drops.
What is Cenderitide used for?
Cenderitide is educationally associated with: Blood pressure reduction, Chronic heart failure treatment, Natriuresis and diuresis promotion, Renal protection in heart failure, Acute decompensated heart failure management, Renal protection, Renin-angiotensin-aldosterone system suppression. Educational only — not medical advice.
How is Cenderitide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Cenderitide?
Reported adverse effects include: Increased serum creatinine, Injection site reactions, Headache, Hypotension, Nausea, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Cenderitide?
Recorded contraindications: Cardiogenic shock, Hypersensitivity to natriuretic peptides, Acute decompensated heart failure with high filling pressures, Severe renal failure (anuria), Severe hypotension. Consult a qualified clinician before use.